simmefafil

Simmefafil (TPN171H) is a potent and selective small molecule inhibitor of phosphodiesterase type 5 (PDE5) developed for the treatment of pulmonary arterial hypertension (PAH). Discovered by the Shanghai Institute of Materia Medica (SIMM) of the Chinese Academy of Sciences, the drug is being co-developed by Suzhou Wangshan Wangshui Biological Medicine and Shandong Tefaman Pharmaceutical. By inhibiting PDE5, simmefafil prevents the breakdown of cyclic guanosine monophosphate (cGMP), which promotes nitric oxide-mediated vasodilation in the pulmonary vasculature, thereby reducing pulmonary arterial pressure and vascular resistance. Clinical development has progressed through Phase 2 trials, where it has been evaluated for its acute hemodynamic effects, safety, and pharmacokinetics in patients with WHO Group 1 PAH, often compared against placebo and active controls like tadalafil.

Other names

Simmefafil